AstraZeneca announces job cuts and new research centres

Biopharmaceutical company AstraZeneca is axing 1,600 jobs as part of plans to invest in new research and development (R&D) centres in the US, UK and Sweden.

Biopharmaceutical company AstraZeneca is axing 1,600 jobs as part of plans to invest in new research and development (R&D) centres in the US, UK and Sweden.

AstraZeneca said it would reduce its headcount and relocate 2,500 roles to the new centres in Cambridge, UK, Gaithersburg, US, and Mlndal, Sweden.

"I recognise that our plans will have a significant impact on many of our people and our stakeholders at the affected sites. We are fully committed to treating all our employees with respect and fairness as we navigate this important period of change," Chief Executive Officer Pascal Soriot said.

The move is part of the firm's effort to improve pipeline productivity and expands its global reach.

Soriot said scientists will be better positioned to form partnerships with world class talent.

"The changes we are proposing represent an exciting and important opportunity to put science at the heart of everything we do because our long-term success depends on improving R&D productivity and achieving scientific leadership," Soriot said.

Under the plans, the company will invest $500m to establish the new Cambridge centre where research and development staff from the existing London and Cheshire facilities will move.

The new Gaithersburg site will become home to the company's US-based global medicines development activities while the Mlndal facility will primarily focus on small molecules.

The proposals are expected to be fully implemented by 2016.

"This is a major investment in the future of this company that will enable us to accelerate innovation by improving collaboration, reducing complexity and speeding up decision-making," Soriet added.

"The strategic centres will also allow us to tap into important bioscience hotspots providing more of our people with easy access to leading-edge academic and industry networks, scientific talent and valuable partnering opportunities."

Shares fell 1.04% to 3,037.50p at 13:21 Monday.

RD

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020

Most Popular

Why we won’t see a house-price crash in 2021
House prices

Why we won’t see a house-price crash in 2021

Lockdown sent house prices berserk as cooped up home-workers fled for bigger properties in the country. And while they won’t rise quite as much this y…
18 Jan 2021
Prepare for the end of the epic bubble in US stocks
US stockmarkets

Prepare for the end of the epic bubble in US stocks

US stocks are as expensive as they’ve ever been. How can you prepare your portfolio for a bubble bursting?
18 Jan 2021
It's not just the UK – we're seeing pandemic housing booms across the globe
Property

It's not just the UK – we're seeing pandemic housing booms across the globe

Soaring house prices aren’t just a UK thing, they’re a worldwide phenomenon. And it’s no coincidence – the underlying cause is much the same. John Ste…
18 Jan 2021